C&W scores drug account, reopens its Chicago office

NEW YORK: Cohn & Wolfe has scooped a new-business win from Genentech, which has awarded it all PR responsibilities for two of its cancer drugs after a summer review of its accounts, said Neil Cohen, the drug maker's director of product communications.

NEW YORK: Cohn & Wolfe has scooped a new-business win from Genentech, which has awarded it all PR responsibilities for two of its cancer drugs after a summer review of its accounts, said Neil Cohen, the drug maker's director of product communications.

Ketchum previously handled PR for Herceptin, a breast cancer drug, and Avastin, for colorectal cancer.

In an active time for C&W, it has also returned to Chicago after leaving three years ago. The firm has named Sherri Jaffe EVP and MD of the new office.

C&W closed its Chicago office in 2001 in its 11th year after it had not reached expectations.

"That market never performed as well as some of our other offices," Steve Aiello, the agency's president at the time, told PRWeek in 2001. The office had revenues of about $3 million in 1998 and $2.5 million in 1999.

Jaffe, a C&W employee from 1999 to 2003, will lead the office's healthcare and consumer practice expansion. She rejoins the firm after serving as group marketing manager at TAP Pharmaceutical Products for a year.

Although Jaffe doesn't officially start until September 8, C&W CEO and president Donna Imperato said that she helped the firm win an undisclosed account this week.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.